F 0758
Level of Harm - Minimal harm
or potential for actual harm
Residents Affected - Few
Implement gradual dose reductions(GDR) and non-pharmacological interventions, unless contraindicated,
prior to initiating or instead of continuing psychotropic medication; and PRN orders for psychotropic
medications are only used when the medication is necessary and PRN use is limited.
**NOTE- TERMS IN BRACKETS HAVE BEEN EDITED TO PROTECT CONFIDENTIALITY** Based on
interview and record review, the facility failed to monitor for side effects of psychotropic medication
(medication given to cause changes in mood, feelings or behavior) for one of three sample residents
(Resident 1). The facility also failed to obtain informed consent before administering psychotropic
medication to Resident 1. Failure to monitor for psychotropic medicaion side effects had the potential to
compromise Resident 1's health. Failure to obtain informed consent had the potential to compromise
Resident 1's ability to make informed decisions regarding his treatment.
Findings:
1. Review of Resident 1's medical record indicated he was admitted on [DATE] and had the diagnosis of
bipolar disorder (a mental health condition that causes extreme mood swings).
Review of Resident 1's Order Summary Report indicated he had a physician's order, dated 11/23/22, for
divalproex sodium (a seizure medication often used as a mood stabilizer) 250 milligrams (mg, unit of dose
measurement) one tablet by mouth at bedtime for bipolar disorder.
Review of Resident 1's medicaion administration record (MAR) indicated he was receiving divalproex
sodium 250 mg at bedtime for bipolar disorder from 11/23/22 until 3/14/23 (except when he refused the
medication). Further review of the medical record indicated there was no documentation that the facility
monitored Resident 1 for side effects of divalproex sodium.
During an interview and concurrent record review with the director of nursing (DON) on 5/10/23 at 11:42
a.m., she stated for residents taking psychotropic medication, the nurses should monitor for side effects
every shift and document this on the MAR. The DON reviewed Resident 1's medical record and confirmed
there was no documentation that the nurses monitored him for side effects of divalproex sodium.
Review of the facility's policy titled Psychotropic Medication Management, revised 10/24/17 indicated,
Medication effects will be monitored and documented on the medication administration record, to include
target behavior monitoring, and monitoring for adverse effects when the medications are used.
2. Review of Resident 1's Order Summary Report indicated he had a physician's order, dated 10/15/22, for
lorazepam (medication used to treat anxiety) 0.5 mg one tablet by mouth every 6 hours as needed for
anxiety.
(continued on next page)
Any deficiency statement ending with an asterisk (*) denotes a deficiency which the institution may be excused from correcting providing it is determined that other
safeguards provide sufficient protection to the patients. (See instructions.) Except for nursing homes, the findings stated above are disclosable 90 days following the
date of survey whether or not a plan of correction is provided. For nursing homes, the above findings and plans of correction are disclosable 14 days following the date
these documents are made available to the facility. If deficiencies are cited, an approved plan of correction is requisite to continued program participation.
LABORATORY DIRECTOR'S OR PROVIDER/SUPPLIER
REPRESENTATIVE'S SIGNATURE
TITLE
(X6) DATE
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Facility ID:
If continuation sheet
Page 1 of 2
Event ID:
555060
Printed: 05/15/2026
Form Approved OMB
No. 0938-0391
Department of Health & Human Services
Centers for Medicare & Medicaid Services
STATEMENT OF DEFICIENCIES
AND PLAN OF CORRECTION
(X1) PROVIDER/SUPPLIER/CLIA
IDENTIFICATION NUMBER:
(X2) MULTIPLE CONSTRUCTION
555060
B. Wing
A. Building
(X3) DATE SURVEY
COMPLETED
05/10/2023
NAME OF PROVIDER OR SUPPLIER
STREET ADDRESS, CITY, STATE, ZIP CODE
Windsor the Ridge Rehabilitation Center
350 Iris Drive
Salinas, CA 93906
For information on the nursing home's plan to correct this deficiency, please contact the nursing home or the state survey agency.
(X4) ID PREFIX TAG
SUMMARY STATEMENT OF DEFICIENCIES
(Each deficiency must be preceded by full regulatory or LSC identifying information)
F 0758
Level of Harm - Minimal harm
or potential for actual harm
Review of Resident 1's MAR, dated 10/2022, indicated he received lorazepam 0.5 mg on 10/16/22,
10/18/22, and 10/20/22.
Resident 1's Facility Verification of Informed Consent for lorazepam was reviewed. The document was
signed and dated 10/24/22 (8 days after Resident 1 received the first dose of lorazepam).
Residents Affected - Few
During an interview and concurrent record review with the medical records director (MRD) on 5/8/23 at 1:27
p.m., she reviewed Resident 1's electronic health record (EHR) and confirmed the Verification of Informed
Consent for lorazepam was dated 10/24/22. The MRD searched Resident 1's EHR and paper chart and
confirmed there was no other Facility Verification of Informed Consent for lorazepam.
During an interview and concurrent record review with the DON on 5/10/22 at 11:40 a.m., she confirmed
the facility must obtain informed consent prior to administering psychotropic medication. The DON reviewed
Resident 1's MAR an acknowledged he received lorazepam on 10/16/22, 10/18/22, and 10/20/22. The DON
reviewed Resident 1's Verification of Informed Consent for lorazepam and confirmed it was dated 10/24/22.
She searched Resident 1's medical record and confirmed there was no Verification of Informed Consent for
lorazepam prior to 10/24/22.
Review of the facility's policy titled Psychotropic Medication Management, revised 10/24/17 indicated,
Informed consent for the use of psychoactive medication must be contained in the clinical record.
FORM CMS-2567 (02/99)
Previous Versions Obsolete
Event ID:
Facility ID:
555060
If continuation sheet
Page 2 of 2